Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377795 | 0.86 | F10 (0.44) | F10 | |
| SCHEMBL4851277 | 0.84 | F10 (0.47) | F10HDAC8HDAC6 | |
| SCHEMBL5386312 | 0.84 | F10 (0.39) | F10 | |
| SCHEMBL5380531 | 0.83 | F10 (0.38) | F10 | |
| SCHEMBL5379823 | 0.83 | F10 (0.38) | F10 | |
| SCHEMBL6359962 | 0.83 | KDM4E (0.36) | F10 | |
| SCHEMBL5371113 | 0.82 | F10 (0.47) | F10 | |
| SCHEMBL5380004 | 0.82 | F10 (0.47) | F10 | |
| SCHEMBL5383367 | 0.81 | F10 (0.36) | F10 | |
| SCHEMBL5467839 | 0.81 | F10 (0.39) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482374-B2 | Pyrrolidine-2-ones as Factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| US-7329685-B2 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| EP-1635817-B1 | 1-PHENYL-2-OXO-3-SULFONYLAMINO-PYRROLIDINE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR XA INHIBITORS FOR THE TREATMENT OF ACUTE VASCULAR DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| US-20060167079-A1 | Pyrrolidine -2-ones as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203206-A1 | 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors | TFPI, F2, F12 | F10 13/4885MAP2K1 4702/4885MAP2K2 4569/4885 |
| US-20060167079-A1 | Pyrrolidine -2-ones as factor xa inhibitors | TFPI, F2, F11 | F10 10/4885MAP2K1 4525/4885MAP2K2 3925/4885 |
| US-20060178419-A1 | 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | F10 11/4885MAP2K1 4340/4885MAP2K2 3959/4885 |
| US-20060148879-A1 | 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases | SERPINE1, PLAT, SERPINC1 | F10 16/4885MAP2K1 3875/4885MAP2K2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.